To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Plasma P-tau181 in Alzhei… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Journal article
Authors S. Janelidze
N. Mattsson
S. Palmqvist
R. Smith
T. G. Beach
G. E. Serrano
X. Y. Chai
N. K. Proctor
U. Eichenlaub
Henrik Zetterberg
Kaj Blennow
E. M. Reiman
E. Stomrud
J. L. Dage
O. Hansson
Published in Nature Medicine
Volume 26
Pages 379-386
ISSN 1078-8956
Publication year 2020
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 379-386
Language en
Keywords mild cognitive impairment, csf t-tau, cerebrospinal-fluid, clinical-diagnosis, national institute, supranuclear palsy, cross-validation, amyloid-beta, p-tau, f-18-av-1451, Biochemistry & Molecular Biology, Cell Biology, Research & Experimental, Medicine
Subject categories Cell biology


Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC) = 0.87-0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC = 0.94-0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials. Plasma P-tau18 level increased with progression of Alzheimer's disease (AD) and differentiated AD dementia from other neurodegenerative diseases, supporting its further development as a blood-based biomarker for AD.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
Utskriftsdatum: 2020-08-15